Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
biotech · Solid Tumors · Pancreatic Cancer · MREO
MEREO BIOPHARMA GROUP
Mereo BioPharma Group plc
MEREO BIOPHARMA GROUP drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4TH FLOOR, ONE, LONDON, USA HQ
4 Employees
Public company Type
MREO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4TH FLOOR, ONE, LONDON, USA
- Employees
- 4
- Programs
- 47
- Drugs
- 22
- Patents
- 18
MEREO BIOPHARMA GROUP pipeline
Portfolio lens on 22 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
MEREO BIOPHARMA GROUP drug portfolio — 22 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
sorafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in MEREO BIOPHARMA GROUP's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.
-
Development asset linked to MEREO BIOPHARMA GROUP in public FDA and regional records.